Combination therapy to checkmate Glioblastoma: clinical challenges and advances

Area of Science:

• Neuro-oncology
• Cancer Pharmacology
• Translational Medicine

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and high recurrence rates.
• Treatment is limited by tumor cell infiltration, the blood-brain barrier, tumor heterogeneity, and drug resistance.
• Combination therapy is a key strategy to overcome these challenges.

Purpose of the Study:

• To review the pathophysiology, diagnostic markers, and therapeutic strategies for glioblastoma.
• To discuss current treatment limitations and novel combination therapies.
• To summarize ongoing clinical trials for glioblastoma therapy.

Main Methods:

• Literature review of preclinical and clinical studies on glioblastoma treatment.
• Analysis of current therapeutic options and emerging combination drug regimens.
• Synthesis of information on diagnostic markers and targeting strategies.

Main Results:

• Combination therapy is a promising approach for glioblastoma, with novel regimens under investigation.
• Understanding glioblastoma pathophysiology is crucial for developing effective treatments.
• Several combination therapies are in various stages of clinical trials.

Conclusions:

• Novel combination therapies hold significant potential for improving glioblastoma treatment outcomes.
• Overcoming treatment resistance and enhancing drug delivery are critical areas of focus.
• Continued research and clinical trials are essential for advancing glioblastoma therapy.